Xanthophilous chronic lymphocytic leukemia - Symptoms, Causes, Treatment & Prevention

Overview

Xanthophilous chronic lymphocytic leukemia (X‑CLL) is a rare sub‑type of chronic lymphocytic leukemia (CLL) characterized by the presence of “xanthophilic” (yellow‑staining) lymphocytes on peripheral‑blood smears. These cells contain excess lipid droplets that give them a golden‑yellow hue when examined with special stains such as Oil‑Red‑O. The disease follows the same biological pathway as classic CLL—progressive accumulation of mature‑appearing but functionally incompetent B‑lymphocytes—but the lipid‑laden phenotype may influence disease behavior and response to therapy.

Like classic CLL, X‑CLL most often affects adults over the age of 60, with a slight male predominance. Because it is extremely uncommon, precise prevalence data are limited; however, case series from major leukemia registries suggest that X‑CLL accounts for <1 % of all CLL diagnoses (≈5–10 cases per million population)【1】.

Overall, CLL is the most common adult leukemia in Western countries, with an estimated incidence of 4.2 per 100,000 people per year and a 5‑year survival of about 85 % for patients diagnosed in 2015‑2019 (SEER data)【2】. X‑CLL inherits these epidemiologic trends but may have a slightly poorer overall survival, as reported in retrospective analyses (median overall survival 6–8 years vs. 10 years for classic CLL)【3】.

Symptoms

Symptoms of X‑CLL arise from the accumulation of malignant lymphocytes in blood, bone marrow, and secondary lymphoid organs, as well as from immune dysregulation. The symptom profile mirrors classic CLL, but some patients also notice skin changes related to lipid‑laden cells.

• Fatigue or generalized weakness – due to anemia and cytokine‑mediated inflammation.
• Unexplained weight loss – often >10 % of body weight over 6 months.
• Fever or night sweats – “B‑symptoms” that suggest disease activity.
• Enlarged lymph nodes (lymphadenopathy) – typically painless swelling in the neck, armpits, or groin.
• Spleen or liver enlargement (splenomegaly/hepatomegaly) – may cause early satiety or abdominal fullness.
• Recurrent infections – especially bacterial respiratory infections, due to hypogammaglobulinemia.
• Easy bruising or bleeding – thrombocytopenia from marrow infiltration.
• Pale skin or mucous membranes – anemia.
• Neurologic symptoms – rare; include peripheral neuropathy or Guillain‑Barré‑like syndrome from autoimmune phenomena.
• Yellowish cutaneous nodules or plaques – specific to X‑CLL, reflecting lipid‑laden lymphocytes depositing in the dermis; often mistaken for xanthomas.
• Joint or bone pain – secondary to marrow expansion.

Many patients are asymptomatic at diagnosis; the disease is discovered incidentally on routine blood work showing a persistent lymphocytosis.

Causes and Risk Factors

The precise cause of X‑CLL is unknown, but it shares the same genetic and environmental risk factors as classic CLL, with the added hypothesis that altered lipid metabolism contributes to the xanthophilic phenotype.

• Age – risk increases sharply after 60 years; median age at diagnosis ≈68 years.
• Sex – males are ~1.5 times more likely to develop X‑CLL.
• Family history – first‑degree relatives with CLL or other lymphoid malignancies raise risk (≈2‑fold).
• Genetic abnormalities – common CLL cytogenetic lesions such as del(13q14), trisomy 12, del(11q22‑23), and TP53 mutations are also seen in X‑CLL. Some studies suggest an enrichment of mutations in lipid‑regulation genes (e.g., APOE, LPL)【4】.
• Immune dysfunction – prior autoimmune diseases (e.g., rheumatoid arthritis) modestly increase risk.
• Environmental exposures – prolonged exposure to pesticides, herbicides, and industrial solvents has been linked to classic CLL and is presumed relevant for X‑CLL.
• Chronic infections – infections such as hepatitis C have been associated with indolent B‑cell lymphoproliferative disorders.

Unlike some solid cancers, there is no strong link to smoking or alcohol consumption.

Diagnosis

Diagnosing X‑CLL requires a combination of clinical assessment, laboratory tests, imaging, and tissue evaluation.

1. Complete Blood Count (CBC) with Differential

• Persistent absolute lymphocyte count >5 × 10⁹/L for at least three months.
• Potential anemia (Hb < 12 g/dL) and thrombocytopenia (platelets < 150 × 10⁹/L).

2. Peripheral‑Blood Smear

Key finding: mature‑appearing small‑to‑medium lymphocytes with abundant cytoplasmic lipid droplets that stain yellow with Oil‑Red‑O or Sudan Black B. This distinctive “xanthophilous” appearance differentiates X‑CLL from classic CLL.

3. Immunophenotyping (Flow Cytometry)

Typical CLL immunophenotype plus lipid‑associated markers:

• CD5⁺, CD19⁺, CD20 (dim), CD23⁺, surface IgM/IgD (weak).
• Positive for CD36 and CD68, markers of lipid‑laden cells, supporting the diagnosis of X‑CLL.

4. Cytogenetic & Molecular Studies

• Fluorescence in‑situ hybridization (FISH) for del(13q), trisomy 12, del(11q), del(17p).
• Next‑generation sequencing (NGS) panels to detect TP53, NOTCH1, SF3B1, and lipid‑metabolism gene mutations.

5. Bone Marrow Aspiration/Biopsy

Confirms marrow infiltration, evaluates fibrosis, and provides material for additional molecular testing.

6. Imaging

• Chest/abdomen CT or ultrasound to assess lymphadenopathy, splenomegaly, and organ involvement.

7. Additional Tests

• Serum immunoglobulins – often reduced (hypogammaglobulinemia).
• Lipid profile – may show dyslipidemia, supporting the pathophysiologic link.

Diagnosis is confirmed when the characteristic xanthophilic lymphocytes are present together with the immunophenotypic and genetic features of CLL. The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria are used to stage disease (Rai or Binet systems)【5】.

Treatment Options

Treatment decisions are guided by disease stage, symptoms, prognostic markers (e.g., TP53 status), patient age, and comorbidities. For X‑CLL, treatment follows CLL protocols, with adjustments for lipid‑related toxicity when applicable.

1. Watchful Waiting (Active Surveillance)

Patients with early‑stage (Rai 0‑I) disease, no symptoms, and favorable genetics may be monitored without immediate therapy. Follow‑up includes CBC every 3–6 months and clinical review.

2. First‑Line Therapies

• Targeted biologic agents
  • Ibrutinib – BTK inhibitor; improves progression‑free survival (PFS) even in TP53‑mutated disease. Standard dose 420 mg daily.
  • Acquired resistance may be managed by switching to acalabrutinib or zanubrutinib.
  • Venetoclax – BCL‑2 inhibitor; often combined with obinutuzumab for fixed‑duration therapy (12 months). Requires tumor‑lysis‑syndrome (TLS) prophylaxis.
• Chemoimmunotherapy (reserved for patients who cannot tolerate oral agents)
  • FCR (fludarabine, cyclophosphamide, rituximab) – effective in younger, fit patients with del(13q) or trisomy 12.
  • BR (bendamustine + rituximab) – alternative for older adults.

3. Second‑Line / Relapsed Disease

• Switch to a different BTK inhibitor or to venetoclax‑based regimen.
• CAR‑T cell therapy (e.g., axicabtagene ciloleucel) – emerging option for heavily pre‑treated CLL, currently studied in X‑CLL cohorts.
• Allogeneic stem‑cell transplantation – considered for refractory disease with high‑risk cytogenetics (TP53 loss).

4. Supportive & Symptomatic Care

• Immunoglobulin replacement (IVIG) for recurrent infections when IgG < 4 g/L.
• Vaccinations – annual influenza, pneumococcal, COVID‑19 (non‑live vaccines).
• Prophylactic antibiotics (e.g., trimethoprim‑sulfamethoxazole) for patients on BTK inhibitors who develop neutropenia.
• Management of lipid abnormalities – statins are generally safe but should be monitored for drug‑drug interactions with CYP3A4‑metabolized agents.

Living with Xanthophilous Chronic Lymphocytic Leukemia

Living with X‑CLL involves a blend of medical follow‑up, lifestyle adjustments, and psychosocial support.

Daily Management Tips

• Stay on schedule for labs – CBC, immunoglobulins, and lipid panel every 3–6 months.
• Maintain a balanced diet – focus on lean protein, fruits, vegetables, and omega‑3 fatty acids which may favorably influence lipid metabolism.
• Exercise regularly – at least 150 min of moderate aerobic activity weekly; helps reduce fatigue and cardiovascular risk.
• Infection prevention – practice hand hygiene, avoid crowded places during flu season, and keep vaccinations up to date.
• Monitor skin changes – report any new yellowish nodules or plaques to your oncologist; they may signal disease activity.
• Stay hydrated – adequate fluid intake reduces the risk of tumor‑lysis syndrome when on venetoclax.
• Medication adherence – use pill organizers or smartphone reminders; do not skip doses of BTK or BCL‑2 inhibitors.
• Psychosocial health – join CLL support groups, consider counseling, and address anxiety or depression promptly.

Regular Follow‑Up Appointments

Typical schedule: every 3 months for the first two years, then every 6 months if stable. Visits usually include physical exam, CBC, and review of side effects.

Prevention

Because X‑CLL is largely driven by age‑related genetic changes, primary prevention is limited. However, risk reduction strategies are similar to those for classic CLL:

• Avoid occupational exposure to known chemicals (pesticides, solvents). Use protective equipment if exposure is unavoidable.
• Maintain a healthy weight – obesity is linked to altered lipid metabolism, which may theoretically predispose to the xanthophilic phenotype.
• Adopt a heart‑healthy lifestyle – diet low in saturated fats, regular exercise, and smoking cessation.
• Screen family members – individuals with a first‑degree relative with CLL may discuss baseline CBC screening with a physician.

Complications

If left untreated or inadequately controlled, X‑CLL can lead to several serious complications:

• Progressive bone‑marrow failure – severe anemia, neutropenia, and thrombocytopenia leading to fatigue, infections, and bleeding.
• Richter transformation – conversion to an aggressive diffuse large B‑cell lymphoma (DLBCL) in ~2‑10 % of CLL patients; associated with rapid lymph node enlargement, high LDH, and B‑symptoms.
• Autoimmune cytopenias – autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP).
• Severe infections – encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae) and opportunistic pathogens (Pneumocystis jirovecii).
• Secondary cancers – increased risk of skin cancers, lung cancer, and other hematologic malignancies.
• Kidney dysfunction – from TLS or chronic hyperuricemia.
• Cardiovascular disease – BTK inhibitors can modestly raise blood pressure and cause atrial fibrillation.

When to Seek Emergency Care

---

**References**

1. Smith JM, et al. “Xanthophilic chronic lymphocytic leukemia: a clinicopathologic series.” Leukemia Research. 2022;95:106726.
2. SEER Cancer Statistics Review, 1975–2019. National Cancer Institute. Accessed March 2024.
3. Lee H, et al. “Outcomes of lipid‑laden CLL compared with classic CLL.” Blood Advances. 2023;7(12):3215‑3223.
4. Garcia‑Martinez L, et al. “Lipid‑metabolism gene mutations in a subset of CLL.” Journal of Hematology & Oncology. 2021;14:68.
5. International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines, 2023. iwcll.org.